Advances in hypothyroidism management: rethinking therapy beyond levothyroxine

Hypothyroidism, a prevalent neuroendocrine disorder characterised by insufficient thyroid hormone production and a wide spectrum of clinical manifestations, affects approximately 5% of the population, with an additional 5% remaining undiagnosed.While levothyroxine remains the golden standard of care, its inability to resolve persistent symptoms in a subset of patients highlights the need for alternative approaches.Combination levothyroxine+liothyronine therapy, though unpopular and underutilised by most physicians, offers potential benefits, particularly when tailored to mimic natural thyroid hormone ratios.Furthermore, emerging therapies show promise in reducing pharmacokinetic fluctuations that limit current advances in hypothyroidism therapy.By addressing the shortcomings of traditional therapies, these innovative approaches aim to improve the quality of life and clinical outcomes for patients with hypothyroidism, especially when the golden standard fails.This review highlights current viable options and explores emerging therapeutic strategies that could potentially optimise current treatment and quality of life, catering for all hypothyroidism patients.

Authors

Institutions

Publication Details

Journal
SA pharmaceutical journal.
Published
2025-09-01
DOI
https://doi.org/10.36303/sapj.3267
Primary Topic
Thyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advances in hypothyroidism management: rethinking therapy beyond levothyroxine

Keith N. Ncube, J Pick, R Ditshego
SA pharmaceutical journal.
Thyroid Disorders and Treatments
article

Advances in hypothyroidism management: rethinking therapy beyond levothyroxine

Keith N. Ncube, J Pick, R Ditshego
article en

Abstract

Hypothyroidism, a prevalent neuroendocrine disorder characterised by insufficient thyroid hormone production and a wide spectrum of clinical manifestations, affects approximately 5% of the population, with an additional 5% remaining undiagnosed.While levothyroxine remains the golden standard of care, its inability to resolve persistent symptoms in a subset of patients highlights the need for alternative approaches.Combination levothyroxine+liothyronine therapy, though unpopular and underutilised by most physicians, offers potential benefits, particularly when tailored to mimic natural thyroid hormone ratios.Furthermore, emerging therapies show promise in reducing pharmacokinetic fluctuations that limit current advances in hypothyroidism therapy.By addressing the shortcomings of traditional therapies, these innovative approaches aim to improve the quality of life and clinical outcomes for patients with hypothyroidism, especially when the golden standard fails.This review highlights current viable options and explores emerging therapeutic strategies that could potentially optimise current treatment and quality of life, catering for all hypothyroidism patients.

SA pharmaceutical journal.Vol. 92(4)
University of Pretoria (ZA)
Openalex Percentile: Top 68%
Thyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Advances in hypothyroidism management: rethinking therapy beyond levothyroxine — Keith N. Ncube, J Pick, et al. · SA pharmaceutical journal. (2025) | TGRS Research Map | TGRS